Author

Youssef Daali

Geneva University and Geneva University Hospitals - Cited by 6,198 - Clinical Pharmacology - Pharmacokinetics - Metabolism - PBPK - analytical chemistry

Biography

Dr. Youssef Daali is an Associate professor in the Department of Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care , Geneva University Hospitals, Geneva, located in Switzerland.
Title
Cited by
Year
Mesoporous silica nanoparticles as pH-responsive carrier for the immune-activating drug resiquimod enhance the local immune response in mice
J Wagner, D Gößl, N Ustyanovska, M Xiong, D Hauser, O Zhuzhgova, ...ACS nano 15 (3), 4450-4466, 2021202
67
2021
Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy
AS Darwich, TM Polasek, JK Aronson, K Ogungbenro, DFB Wright, ...Annual Review of Pharmacology and Toxicology 61, 225-245, 2021202
63
2021
The tyrosine kinase inhibitor nilotinib inhibits SARS‐CoV‐2 in vitro
V Cagno, G Magliocco, C Tapparel, Y DaaliBasic & clinical pharmacology & toxicology 128 (4), 621-624, 2021202
40
2021
Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail
C Lenoir, Y Daali, V Rollason, F Curtin, Y Gloor, M Bosilkovska, B Walder, ...Clinical Pharmacology & Therapeutics 109 (6), 1668-1676, 2021202
40
2021
Impact of SARS‐CoV‐2 infection (COVID‐19) on cytochromes P450 activity assessed by the Geneva cocktail
C Lenoir, J Terrier, Y Gloor, F Curtin, V Rollason, JA Desmeules, Y Daali, ...Clinical Pharmacology & Therapeutics 110 (5), 1358-1367, 2021202
29
2021
Optimized low‐dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment
M Zoetemelk, GM Ramzy, M Rausch, T Koessler, JR van Beijnum, ...Molecular oncology 14 (11), 2894-2919,
20
2020
Reviewing data integrated for PBPK model development to predict metabolic drug-drug interactions: Shifting perspectives and emerging trends
K Abouir, CF Samer, Y Gloor, JA Desmeules, Y DaaliFrontiers in Pharmacology 12, 708299, 2021202
17
2021
Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity
G Magliocco, J Desmeules, A Matthey, LM Quirós‐Guerrero, N Bararpour, ...British Journal of Pharmacology 178 (23), 4708-4725, 2021202
15
2021
Is pain temporary and glory forever? Detection of tramadol using dried blood spot in cycling competitions
O Salamin, A Garcia, V González‐Ruiz, F Rossi, X Bigard, J Déglon, ...Drug testing and analysis 12 (11-12), 1649-1657, 2020202
13
2020
Liquid biopsy for patient characterization in cardiovascular disease: verification against markers of cytochrome P450 and P‐glycoprotein activities
B Achour, P Gosselin, J Terrier, Y Gloor, ZM Al‐Majdoub, TM Polasek, ...Clinical Pharmacology & Therapeutics 111 (6), 1268-1277, 2022202
13
2022
Drug-drug interactions with direct oral anticoagulants: practical recommendations for clinicians
J Terrier, F Gaspar, P Fontana, Y Daali, JL Reny, C Csajka, CF SamerThe American Journal of Medicine 134 (8), 939-942, 2021202
12
2021
Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study
K Ben Hassine, T Nava, Y Théoret, CE Nath, Y Daali, N Kassir, V Lewis, ...CPT: Pharmacometrics & Systems Pharmacology 10 (9), 1043-1056, 2021202
11
2021
Evaluation of phenotypic and genotypic variations of drug metabolising enzymes and transporters in chronic pain patients facing adverse drug reactions or non-response to …
V Rollason, C Lloret-Linares, KI Lorenzini, Y Daali, M Gex-Fabry, V Piguet, ...Journal of personalized medicine (4), 198, 2020202
10
2020
Deep proteomics and phosphoproteomics reveal novel biological pathways perturbed by morphine, morphine‐3‐glucuronide and morphine‐6‐glucuronide in human astrocytes
V Dozio, Y Daali, J Desmeules, JC SanchezJournal of neuroscience research 100 (1), 220-236, 2022202
9
2022
CYP450 genotype—Phenotype concordance using the geneva micrococktail in a clinical setting
K Ing Lorenzini, J Desmeules, V Rollason, S Bertin, M Besson, Y Daali, ...Frontiers in Pharmacology 12, 730637, 2021202
8
2021
Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting
C Lenoir, J Terrier, Y Gloor, P Gosselin, Y Daali, C Combescure, ...Journal of Personalized Medicine 12 (4), 526, 2022202
8
2022
Frequency of important cyp450 enzyme gene polymorphisms in the Iranian population in comparison with other major populations: a comprehensive review of the human data
N Neyshaburinezhad, H Ghasim, M Rouini, Y Daali, YH ArdakaniJournal of Personalized Medicine 11 (8), 804, 2021202
7
2021
Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressants
Y Gloor, C Lloret-Linares, M Bosilkovska, N Perroud, H Richard-Lepouriel, ...Biomedicine & Pharmacotherapy 152, 113202, 2022202
7
2022
Safety of the Geneva cocktail, a cytochrome P450 and P-glycoprotein phenotyping cocktail, in healthy volunteers from three different geographic origins
V Rollason, M Mouterde, Y Daali, M Čížková, E Priehodová, I Kulichová, ...Drug safety 43, 1181-1189, 2020202
6
2020
Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics
Prediction of cytochromes P40 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokineticsC Lenoir, A Niederer, V Rollason, JA Desmeules, Y Daali, CF SamerCPT: Pharmacometrics & Systems Pharmacology 11 (1), 30-43, 2022202
5
2022

Referred From: https://scholar.google.com/citations?hl=en&user=zOnHLOEAAAAJ

Cited by
Citations 6198
h-index 42
i10-index 109
Recommended Journals
Open Access Journals